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compared to those reported in Veneto-Trentino Alto Adige (Italy), Israel,
Victoria (Australia), and Wisconsin and Colorado (US). The current
incidence was compared to that observed in the other European countries
that recently reported their experience in NBS for CF.
Results: Over the 43-year period, the incidence of CF was estimated at
1/2811 in Brittany. Poisson regression showed that the incidence decreased
significantly over the study period (annual APC: − 1.8%, p < 0.0001). It
dropped from 1/1983 over the 1975–79 period to 1/3992 over the 2015-17
period, leading to a decline of 50.3% (p = 0.0019). Comparison with other
areas revealed that: 1°) most areas reported a decline in incidence, but not
all; 2°) themost significant declines were observed in areas where a carrier
screening program was implemented; 3°) although halved, the incidence
of CF in Brittany remained among the highest reported in Europe.
Conclusion: This study highlights how the incidence of CF has evolved in
an areawhere CF is frequent. It reports a clear drop in incidence that results
from a complex mixture of factors. Comparison with other areas help to
better understand factors influencing the incidence, which depends
notably on the health policies implemented on CF.
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The European Cystic Fibrosis Society Patient Registry (ECFSPR) collects
anonymised demographic and clinical data from consenting people with
CF in Europe. The aim of this study is to describe the adult populationwith
CF in Europe.
We considered patients of 18 years or older in the 2017 data, the latest year
of follow-up available. Countries with a coverage below 80% were not
considered when reporting figures by country. Percentages are computed
for categorical variables; quartiles for numerical variables.
For the year 2017, the ECFSPR database contains data of 48,204 patients
from 35 countries. 24,491 (51.3%) are adults.
The percentage of adults varies from 6.5% in Albania to 62.8% in Sweden.
The proportion of adult females varies from 37.1% in North Macedonia to
59.6% in Slovenia. The highest percentage of patients living with lung
transplant is 22.7% in Slovenia.
Considering patients of 18–29 years, the lowest percentage of chronic
Pseudomonas Aeruginosa is 30.6% in France, the highest is 79.4% in Serbia.
For chronic Burkholderia cepacia complex species the lowest percentage of
infected patients is 2.5% in Italy, the highest 20.6% in Serbia. The lowest
percentage of CF related diabetes is 7.3% in Slovak Republic, the highest
34.2% in the Czech Republic. Median of BMI changes from 18.8 in the
Russian Federation to 22.4 kg/m2 in Luxembourg. Considering patients not
transplanted, we observe a percentage of patients with FEV1% below 40%
that varies from 3.0% in Denmark to 28.5% in the Russian Federation.
We considered only countries with a coverage of 80% or higher, for a
realistic reflection of CF and observed variation among those countries.
Data show that the percentage of adult population is higher in North
Europe, infections are more frequent in Eastern Europe and growth and
lung function areworse in Eastern Europe. Further investigation is required
to investigate differences in healthcare systems to plan an adequate
development of CF care services for adult CF people.
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Objectives: The annual rate of change in lung function is an important
measure of disease progression.We sought to determine the rate of decline
of percent predicted FEV1 (ppFEV1) for adults attending UK CF centres,
accounting for age, sex and pancreatic status.
Methods: Data on ppFEV1 were obtained from the UK Cystic Fibrosis
registry from 2015–2017. Patients post-lung transplant were excluded.
Multilevel modelling was conducted to calculate the annual rate of change
in lung function accounting for sex and age in pancreatic insufficient (PI)
and sufficient (PS) adults.
Table 1.
Rate of Decline in ppFEV1 predicted in One Year in Adults with CF
Pancreatic Insufficient Pancreatic Sufficient
N Mean
annual
change
in
ppFEV1
95%
Confidence
intervals
N Mean
annual
change
in
ppFEV1
95%
Confidence
intervals
18–28 years Females 1124 −1.76 −2.06 to −1.46 171 −1.01 −1.84 to −0.19
Males 1287 −1.61 −1.91 to −1.31 119 −0.53 −1.39 to 0.33
29–39 years Females 608 −1.49 −1.85 to −1.13 133 −0.74 −1.47 to −0.02
Males 851 −1.31 −1.60 to −1.02 125 −0.86 −1.96 to 0.23
40–50 years Females 217 −1.42 −1.98 to −0.87 94 −0.79 −1.60 to 0.01
Males 301 −1.15 −1.59 to −0.71 109 −0.13 −1.01 to 0.75
51+ years Females 81 −1.61 −2.64 to −0.58 92 −0.51 −1.45 to 0.43
Males 148 −1.06 −1.66 to −0.46 75 0.86 −0.23 to 1.95
Results: Overall, ppFEV1 declined annually by −1.52% (95% CI: −1.66 to
−1.38%) and −0.55% (95% CI: −0.86 to −0.23%) in those PI and PS
respectively. In PI patients, females had a greater rate decline in ppFEV1.
The fastest rate of decline was observed in PI individuals between the ages
of 18–28 years (Table 1). The patternwas more inconsistent between sexes
and age categories in those PS (Table 1). The largest annual rate of decline in
ppFEV1 was seen in 18–28 years old females, with the effect reducing with
age. In contrast, men aged 29–39 years had the largest decrease in ppFEV1
and by age 51+ years there was no statistically significant change.
Conclusions: PI individuals had three times the average rate of decline of
those PS. Younger adults, especially females tended to have a faster rate of
decline and need close monitoring.
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Objectives: Our aim was to estimate the effect of air pollution on disease
severity among patients with cystic fibrosis (CF) in Great Britain (GB).
Methods: We used a semi-ecological small-area study design. High-
resolution (100 × 100 m) modelled surfaces of NO2 (2009) and PM2.5 (2010)
concentrations in GB, based on land use regression models, were obtained
from the Small-Area Health Statistics Unit, Imperial College London.
Exposures were assigned based on postcode of residence. CF data for 2016
wereobtainedfromtheUKCFRegistry, acentraliseddatabasewhich, for2016,
included records of 9,297patients fromall CF specialist centres acrossGB.We
used two common proxies of disease severity: the percent predicted forced
expiratory volume in 1 second (ppFEV1%) and the annual numberof days on
intravenous antibiotics for pulmonary exacerbation (#IVdays). Linear and
Poisson regressions, adjusted for age, gender and deprivation (2015 Index of
Multiple Deprivation), were used to explore the association between
exposures (NO2 and PM2.5) and outcomes (ppFEV1% and #IVdays).
Results: Excluding CF patients < 6 years old (n = 1,493) and those with
a missing postcode (n = 64), 7,740 patients were included. Mean ppFEV1%
and #IVdays were 70.5% (standard deviation (SD): 24%) and 19 (SD: 31)
days, respectively. Annual mean concentrations ranged between 2.6 and
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